A novel therapy using Pirfenidone for muscular dystrophy and esophageal mucosal stenosis after endoscopic therapies

• Project/Area Number: 25460664
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Sojo University
• Principal Investigator: UCHIDA Yuji 崇城大学, 薬学部, 准教授 (70433026)
• Co-Investigator(Kenkyū-buntansha): KIMURA En 独立行政法人国立精神・神経医療研究センター, トランスレーショナルメディカルセンター, 室長 (60433025)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2014: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: ピルフェニドン / 線維化 / 炎症性サイトカイン / コラーゲン1

Outline of Final Research Achievements

We focused the inflammation concerning macrophage that is the common key cell between muscular dystrophy and esophageal mucosal stenosis caused after endoscopic therapies. We investigated the amount of cytokine secreted by THP-1 cells induced by CSE or poly(I:C) by ELISA. The result showed that the increase of IL-8 is most obvious. So, we used IL-8 as a parameter of the effect of pirfenidone. Pirfenidone reduced IL-8. The system is simple and useful for the screening of drugs for chronic inflammation.